Cardiovascular complications caused by advanced secondary hyperparathyroidism in chronic dialysis patients; special focus on dilated cardiomyopathy

被引：22

作者：

Goto N. ^{[1
,2
]}

Tominaga Y. ^{[2
]}

Matsuoka S. ^{[2
]}

Sato T. ^{[2
]}

Katayama A. ^{[2
]}

Haba T. ^{[2
]}

Uchida K. ^{[2
]}

机构：

[1] Nagoya Daini Red Cross Hospital, Showa-ku, Nagoya 466-8650

[2] Department of Surgery, Renal Center, Nagoya Second Red Cross Hospital, Nagoya

来源：

Clinical and Experimental Nephrology | 2005年 / 9卷 / 2期

关键词：

Dialysis; Dilated cardiomyopathy; Secondary hyperparathyroidism;

D O I：

10.1007/s10157-005-0351-1

中图分类号：

学科分类号：

摘要：

Background. The frequency and prognosis of dilated cardiomyopathy (DCM) caused by secondary hyperparathyroidism (2°HPT) is not known. The purpose of this study was to determine the morbidity of DCM caused by 2°HPT and the efficacy of parathyroidectomy (PTx) in chronic dialysis patients with advanced 2°HPT was analyzed prospectively. Methods. Between November 2000 and January 2003, 237 dialysis patients who underwent total PTx with forearm autograft at our department were enrolled in this study. Cardiac complications that existed before PTx were examined. Ten patients (4%) had DCM without valvular disease (VD) or ischemic heart disease (IHD). In these 10 patients with DCM before operation, we estimated left ventricular (LV) function at 6 months after PTx, according to echocardiography findings and clinical symptoms. Results. Six months after PTx, left ventricular ejection fraction (LVEF) in these 10 patients was significantly improved, from 31.0 ± 9.8% before PTx, to 56.8 ± 13.5% (P = 0.0003), and left ventricular end-diastolic dimension (LVDd) was reduced, from 59.8 ± 9.7 mm to 46.3 ± 7.0 mm (P = 0.0014). The symptoms due to DCM and the fall of blood pressure that had occurred during dialysis were clearly improved after PTx. Conclusions. Advanced 2°HPT can influence LV function, and in patients who suffered from DCM, LV function was dramatically improved by PTx. PTx should be performed immediately in patients with DCM caused by 2°HPT. © Japanese Society of Nephrology 2005.

引用

页码：138 / 141

页数：3

共 17 条

[1]

Statistical Investigation Committee. An overview of dialysis treatment in Japan, J Jpn Soc Dial Ther, 31, pp. 1-24, (1998)

[2]

Longenecker J.C., Coresh J., Powe N.R., Levey A.S., Fink N.E., Martin A., Et al., Traditional cardiovascular disease risk factors in dialysis patients compared with the general population, the CHOICE Study, J Am Soc Nephrol, 13, pp. 1918-27, (2002)

[3]

Ganesh S.K., Stack A.G., Levin N.W., Hulbert-Shearon T., Port F.K., Association of elevated PO(4), Ca×PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic haemodialysis patients, J Am Soc Nephrol, 12, pp. 2131-8, (2001)

[4]

Nagashima M., Hashimoto K., Shinsato T., Et al., Marked improvement of left ventricular function after parathyroidectomy in a hemodialysis patient with secondary hyperparathyroidism and left ventricular dysfunction, Circ J, 67, pp. 267-72, (2003)

[5]

Tominaga Y., Surgical management of secondary hyperparathyroidism in uremia, Am J Med Sci, 317, pp. 390-7, (1999)

[6]

London G., Parfrey P.S., Cardiac disease in chronic uremia: Pathogenesis, Adv Renal Replac Ther, 4, pp. 194-211, (1997)

[7]

Lin C.L., Hung C.C., Yang C.T., Huang C.C., Improved anemia and reduced erythropoietin need by medical or surgical intervention of secondary hyperparathyroidism in hemodialysis patients, Ren Fail, 26, pp. 289-95, (2004)

[8]

Bogin E., Massry S.G., Harary I., Effect of parathyroid hormone on rat heart cells, J Clin Invest, 67, pp. 1215-27, (1981)

[9]

Amann K., Wiest G., Klaus G., Et al., The role of parathyroid hormone in the genesis of interstitial cell activation in uremia, J Am Soc Nephrol, 4, pp. 1814-19, (1994)

[10]

London G.M., Fabiani F., Marchais S.J., Et al., Uremic cardiopathy: An inadequate left ventricular hypertrophy, Kidney Int, 31, pp. 973-80, (1987)

← 1 2 →